Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer: US Oncologist Survey

The Assessment Group, January 2011, Pages: 31

Patient specific case scenarios that unfold throughout the report, presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment.

Patient case highlights:

In treating an 85-year-old woman presenting with hip pain who was diagnosed with ER/PR positive HER2/neu negative metastatic breast cancer and who underwent a simple mastectomy, 9 of 10 oncologists would recommend xx….To treat her breast cancer, 5 in 10 oncologists would choose…

In a 60-year-old woman with diabetes, hypertension, renal insufficiency, and chronic obstructive pulmonary disease who found a lump in her breast and tests revealed metastatic lesions in ribs, spine, and femur initially treated with…

Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer.

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

- Understand what occurs with actual patients
- Access the most up-to-date prescribing trends
- Gain actionable data for developing and improving your market strategies
- Pinpoint needs of your target audience
- Focus resources to maximize the effectiveness of your budget
- Understand where your product fits
- Understand where your competitor's product fits

Executive Summary

Chapter 1: Introduction

Table 1. Treatment Options in Metastatic Breast Cancer

Chapter 2: Respondent Demographics

Table 2. Eligibility Criteria for Survey Participation

Figure 2.1 Gender of Survey Respondents

Figure 2.2 Years since Medical School Graduation

Figure 2.3 Practice Settings

Figure 2.4 Practices in NCI Cancer Centers

Figure 2.5 Geographic Settings

Figure 2.6 Survey Respondents by State's Breast Cancer Mortality

Figure 2.7 Number of Physicians in Practice Groups

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

Chapter 3: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer

Figure 3.1 Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer

Figure 3.2 Other than analgesics, treatment of patient's hip pain with ER/PR positive HER2/neu negative metastatic breast cancer

Figure 3.3 Treatment with ER/PR positive HER2/neu negative metastatic breast cancer

Figure 3.4 Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer

Factors Influencing Treatment Choice with ER/PR positive HER2/neu Negative Metastatic Breast Cancer

Figure 3.5 Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer

Chapter 4: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer with Comorbidities

Figure 4.1 Confidence managing patient with metastatic breast cancer with multiple comorbidities

Figure 4.2 Barriers to managing patient, metastatic breast cancer with multiple comorbidities

Figure 4.3 Treatment in addition to the aromatase inhibitor for patient's metastatic breast cancer with multiple comorbidities

Figure 4.4 Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities

Figure 4.5 Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities

Chapter 5: Summary

Appendix A: Survey Instrument

- Pfizer
- Astra Zeneca
- Genentech
- Centocor Biotech
- Eli Lilly
- Eisai
- GlaxoSmithKline
- Bristol-Myers Squibb
- Sanofi-aventis
- Amgen
- Novartis

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Positioning of Current and Emerging Targeted Agents in Breast Cancer: Physician & Payer Perspective on Treatment and Reimbursement Decisions in Europe
• Gastric Cancer (Event Driven)
• Personalized Medicine - Scientific and Commercial Aspects
• Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
• Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
• Global Breast Cancer Epidemiology and Patient Flow Analysis - 2012
• Prostate Cancer (Event Driven)
• Breast Cancer Drug Discoveries: What the Future Holds
• Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake
• Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2012